Zentalis Pharmaceuticals, Inc.(ZNTL)

Biotechnology · San Diego, CA

$2.67-0.11 (-3.96%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

Price/FCF Ratio: N/A

Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The Price/FCF ratio is N/A as of 2026-10-06T21:39:17.480Z.

Stored calculation inputs

Calculation as of: 2026-10-06T21:39:17.480Z.

Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 190,067,549
TTM free cash flow · period ending 2026-06-30: -161,119,000

FMP input reference: e5b22bec38318fdeba07533daebf1876a752163d7d28918210f347f826af404f

P/E Ratio|FCF Growth|Operating Margin|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

ZNTL Price/FCF Ratio Metrics

PRICE/FCF RATIO

N/A

ZNTL Competitors' Price/FCF Ratio

ZNTL

Zentalis Pharmaceuticals, Inc.

Current

Market Cap

$190.07M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ELDN

Eledon Pharmaceuticals, Inc.

vs ZNTL

Market Cap

$189.11M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

RXST

RxSight, Inc.

vs ZNTL

Market Cap

$192.49M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SRZN

Surrozen, Inc.

vs ZNTL

Market Cap

$197.18M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ANTX

AN2 Therapeutics, Inc.

vs ZNTL

Market Cap

$182.60M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

XGN

Exagen Inc.

vs ZNTL

Market Cap

$197.87M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

RNAC

Cartesian Therapeutics, Inc.

vs ZNTL

Market Cap

$198.33M

Price/FCF Ratio

N/A

TTM Avg

10.25

3Y Avg

10.25

5Y Avg

10.25

CNTN

Canton Strategic Holdings Inc

vs ZNTL

Market Cap

$180.47M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CMPX

Compass Therapeutics, Inc.

vs ZNTL

Market Cap

$179.75M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ORMP

Oramed Pharmaceuticals Inc.

vs ZNTL

Market Cap

$179.26M

Price/FCF Ratio

N/A

TTM Avg

28.71

3Y Avg

28.66

5Y Avg

28.66

NAME	MARKET CAP	PRICE/FCF RATIO	TTM	3Y	5Y
Zentalis Pharmaceuticals, Inc. (ZNTL)	$190.07M	N/A	N/A	N/A	N/A
Eledon Pharmaceuticals, Inc. (ELDN)vs ›	$189.11M	N/A	N/A	N/A	N/A
RxSight, Inc. (RXST)vs ›	$192.49M	N/A	N/A	N/A	N/A
Surrozen, Inc. (SRZN)vs ›	$197.18M	N/A	N/A	N/A	N/A
AN2 Therapeutics, Inc. (ANTX)vs ›	$182.60M	N/A	N/A	N/A	N/A
Exagen Inc. (XGN)vs ›	$197.87M	N/A	N/A	N/A	N/A
Cartesian Therapeutics, Inc. (RNAC)vs ›	$198.33M	N/A	10.25	10.25	10.25
Canton Strategic Holdings Inc (CNTN)vs ›	$180.47M	N/A	N/A	N/A	N/A
Compass Therapeutics, Inc. (CMPX)vs ›	$179.75M	N/A	N/A	N/A	N/A
Oramed Pharmaceuticals Inc. (ORMP)vs ›	$179.26M	N/A	28.71	28.66	28.66

Free Cash Flow Valuation

P/FCF Ratio

N/A

FCF Yield

N/A

Price/FCF Ratio Formula & Definition

P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Price/FCF Ratio: N/A

ZNTL Price/FCF Ratio Metrics

ZNTL Competitors' Price/FCF Ratio

Free Cash Flow Valuation

Price/FCF Ratio Formula & Definition

Related Metrics